Khalil, Bilal
Linsenmeier, Miriam
Smith, Courtney L.
Shorter, James
Rossoll, Wilfried http://orcid.org/0000-0002-9622-541X
Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (R33NS110960)
National Institute on Aging (RF1AG068581, RF1AG076122, R01AG077771, R01AG077771, R21AG061784, R21AG065854)
Target ALS
ALS Association
Doctorate Fellowship Foundation of Nanjing Forestry University
Robert Packard Center for ALS Research, Johns Hopkins University
Office of the Secretary of Defense (W81XWH-19–1-0193)
Office of the Secretary (W81XWH-20-1-0242)
G. Harold and Leila Y. Mathers Foundation
Sanofi
National Institute of General Medical Sciences (R01GM099836)
Mayo Clinic
BrightFocus Foundation (A2021038S)
Article History
Received: 5 June 2023
Accepted: 13 December 2023
First Online: 22 January 2024
Declarations
:
: Not applicable.
: Not applicable.
: BK, ML, CS and WR declare they have no financial competing interests. BK and WR are co-inventors on a patent relating to the content of the manuscript. JS is a consultant for Dewpoint Therapeutics, ADRx, and Neumora, and shareholder and advisor for Confluence Therapeutics.